Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Britannia Life SciencesBLSIF Price-to-Tangible-Book is 0.65 as of Sep. 01, 2026. The stock has 5 warning signs investors should review. Among 1,129 Biotechnology companies, Britannia Life Sciences ranks better than 95.31% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Britannia Life Sciences Price-to-Tangible-Book Related Terms
Britannia Life Sciences Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Britannia Life Sciences's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Britannia Life Sciences Price-to-Tangible-Book Chart
BLSIF vs VRTX, REGN, MRNA: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Britannia Life Sciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Britannia Life Sciences Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Britannia Life Sciences's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Britannia Life Sciences's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Britannia Life Sciences (BLSIF) has a Price-to-Tangible-Book of 0.65 as of Sep. 01, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Britannia Life Sciences and its competitors. According to the industry distribution chart, Britannia Life Sciences ranks #53 out of 1129 companies in the Biotechnology industry, placing it in the top 4.7%.
Is Britannia Life Sciences' Price-to-Tangible-Book too high?
Britannia Life Sciences' current Price-to-Tangible-Book is 0.65. The Biotechnology industry median Price-to-Tangible-Book is 3.25. Britannia Life Sciences' value of 0.65 is 80% below this industry median. Based on the distribution chart, Britannia Life Sciences ranks #53 out of 1129 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Britannia Life Sciences' Price-to-Tangible-Book compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Britannia Life Sciences ranks #53 out of 1129 companies for Price-to-Tangible-Book. This places Britannia Life Sciences in the top 5% of its industry — outperforming the majority of peers. The industry median Price-to-Tangible-Book is 3.25. Britannia Life Sciences' value of 0.65 is 80% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.25, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Britannia Life Sciences's current Price-to-Tangible-Book of 0.65 is 80% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Britannia Life Sciences and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Britannia Life Sciences's current Price-to-Tangible-Book is 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Britannia Life Sciences stock overvalued right now?
Britannia Life Sciences (BLSIF) has a current Price-to-Tangible-Book of 0.65. The current Price-to-Tangible-Book is 0.65 and 80% below the Biotechnology industry median of 3.25. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Britannia Life Sciences (BLSIF), the current Price-to-Tangible-Book is 0.65 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Britannia Life Sciences Inc provides product testing, safety assessment, and manufacturing services to the cosmetic and consumer packaged goods industries in the United Kingdom and globally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLSIF has been successfully added to your 
